Neoadjuvant Treatment Improves Prognosis in High CA19-9 Pancreatic Cancer Patients

Patients with high pre-treatment CA19-9 levels show significantly poorer prognoses than those with normal levels. Neoadjuvant treatment (NAT) markedly enhances survival for these patients, with optimal outcomes for those achieving normalized CA19-9 or sufficient reduction post-treatment. Stratification reveals that patients with levels under 296 u/ml and over 40% reduction mirror the prognosis of those with normalized levels, while those with higher post-NAT levels face dire outcomes.